Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis and Hair Loss

Erlotinib, a tyrosine kinase inhibitor (EGFR-TKI), its use is frequently accompanied by significant cutaneous side effects, including facial dermatitis and hair loss. Previous research suggests that substance P (SP), a neuropeptide, is a major mediator of this skin toxicity. Given aprepitant’s…